Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas

Cytokine-Induced Killer Cells Clinical Trial

Official title:
A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Stage I-II Malignant Gliomas

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant Glioma is also evaluated.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02494804
Study type	Interventional
Source	The First People's Hospital of Changzhou
Contact	Changping Wu, M.D
Phone	8651968870978
Email	wcpjjt@163.com
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	July 2015
Completion date	July 2030

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03084809` - Chemotherapy Combined With CIK Treating Colon Cancer	Phase 4
	Not yet recruiting	`NCT02496988` - Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas	Phase 4